Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus

• Published in: Atherosclerosis 2003, Vol.166 (1), p.129-135
• Main Authors: van de Ree, M.A, Huisman, M.V, Princen, H.M.G, Meinders, A.E, Kluft, C
• Format: Article
• Language: English
• Subjects: Aged; Atorvastatin; Biological and medical sciences; Body Mass Index; C-Reactive Protein - analysis; C-Reactive Protein - drug effects; Diabetes mellitus; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Double-Blind Method; Female; General and cellular metabolism. Vitamins; Heptanoic Acids - administration & dosage; Heptanoic Acids - pharmacology; Heptanoic Acids - therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Inflammation; Interleukin-6 - blood; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Pyrroles - administration & dosage; Pyrroles - pharmacology; Pyrroles - therapeutic use; Risk factors; Treatment Outcome
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/S0021-9150(02)00316-7

Objective: Statins are known to reduce CRP concentrations, but whether high doses are more effective is not known. Methods: In a prospective double-blind multicenter study in 186 DM2 patients without manifest coronary artery disease and with dyslipidemia, the effect of a 30-week treatment with 10 and 80 mg atorvastatin or placebo on the reduction of hs-CRP levels was measured. Results: Median CRP levels increased with 6.6% in the placebo group and were reduced by 15 and 47%, respectively, with atorvastatin 10 and 80 mg ( P